

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Murphy on or about 9 April 2008.

The application has been amended as follows:

1. In claim 24, lines 1 and 2 thereof were deleted and the following inserted in lieu thereof: -- A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate as claimed in claim 1 and a pharmaceutically acceptable carrier or diluent. -- .
2. In claim 25, lines 1 and 2 thereof were deleted and the following inserted in lieu thereof: -- A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate as claimed in claim 6 and a pharmaceutically acceptable carrier or diluent. -- .
3. In claim 26, lines 1 and 2 thereof were deleted and the following inserted in lieu thereof: -- A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate as claimed in claim 9 and a pharmaceutically acceptable carrier or diluent. -- .
4. In claim 27, lines 1 and 2 thereof were deleted and the following inserted in lieu thereof: -- A pharmaceutical composition comprising a polymorphic form of

tolterodine tartrate as claimed in claim 12 and a pharmaceutically acceptable carrier or diluent. -- .

5. In claim 28, lines 1 and 2 thereof were deleted and the following inserted in lieu thereof: -- A pharmaceutical composition comprising a polymorphic form of tolterodine tartrate as claimed in claim 17 and a pharmaceutically acceptable carrier or diluent. -- .

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter G. O'Sullivan whose telephone number is (571)272-0642. The examiner can normally be reached on M-F 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter G O'Sullivan/
Primary Examiner, Art Unit 1621